Literature DB >> 26921451

Effects of different isoforms of apoE on aggregation of the α-synuclein protein implicated in Parkinson's disease.

Fatemeh Nouri Emamzadeh1, Harmesh Aojula2, Patrick C McHugh3, David Allsop1.   

Abstract

Parkinson's disease is a progressive brain disorder due to the degeneration of dopaminergic neurons in the substantia nigra. The accumulation of aggregated forms of α-synuclein protein into Lewy bodies is one of the characteristic features of this disease although the pathological role of any such protein deposits in causing neurodegeneration remains elusive. Here, the effects of different apolipoprotein E isoforms (apoE2, apoE3, apoE4) on the aggregation of α-synuclein in vitro were examined using thioflavin T assays and also an immunoassay to detect the formation of multimeric forms. Our results revealed that the aggregation of α-synuclein is influenced by apoE concentration. At low concentrations of apoE (<15nM), all of the isoforms were able to increase the aggregation of α-synuclein (50μM), with apoE4 showing the greatest stimulatory effect. This is in contrast to a higher concentration (>15nM) of these isoforms, where a decrease in the aggregation of α-synuclein was noted. The data show that exceptionally low levels of apoE may seed α-syn aggregation, which could potentially lead to the pathogenesis of α-synuclein-induced neurodegeneration. On the other hand, higher levels of apoE could potentially lower the degree of α-synuclein aggregation and confer protection. The differential effects noted with apoE4 could explain why this particular isoform results in an earlier age of onset for Parkinson's disease.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Aggregation; Apolipoprotein E; Lewy body; Parkinson’s disease; α-Synuclein

Mesh:

Substances:

Year:  2016        PMID: 26921451     DOI: 10.1016/j.neulet.2016.02.042

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

Review 1.  Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.

Authors:  Tien-Phat V Huynh; Albert A Davis; Jason D Ulrich; David M Holtzman
Journal:  J Lipid Res       Date:  2017-02-27       Impact factor: 5.922

2.  APOE genotype regulates pathology and disease progression in synucleinopathy.

Authors:  Albert A Davis; Casey E Inman; Zachary M Wargel; Umber Dube; Brittany M Freeberg; Alexander Galluppi; Jessica N Haines; Dhruva D Dhavale; Rebecca Miller; Fahim A Choudhury; Patrick M Sullivan; Carlos Cruchaga; Joel S Perlmutter; Jason D Ulrich; Bruno A Benitez; Paul T Kotzbauer; David M Holtzman
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 17.956

Review 3.  Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets.

Authors:  Lijun Dai; Li Zou; Lanxia Meng; Guifen Qiang; Mingmin Yan; Zhentao Zhang
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

Review 4.  APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer's disease pathology and brain diseases.

Authors:  Rosalía Fernández-Calle; Sabine C Konings; Javier Frontiñán-Rubio; Juan García-Revilla; Lluís Camprubí-Ferrer; Martina Svensson; Isak Martinson; Antonio Boza-Serrano; José Luís Venero; Henrietta M Nielsen; Gunnar K Gouras; Tomas Deierborg
Journal:  Mol Neurodegener       Date:  2022-09-24       Impact factor: 18.879

5.  APOE4 exacerbates α-synuclein pathology and related toxicity independent of amyloid.

Authors:  Na Zhao; Olivia N Attrebi; Yingxue Ren; Wenhui Qiao; Berkiye Sonustun; Yuka A Martens; Axel D Meneses; Fuyao Li; Francis Shue; Jiaying Zheng; Alexandra J Van Ingelgom; Mary D Davis; Aishe Kurti; Joshua A Knight; Cynthia Linares; Yixing Chen; Marion Delenclos; Chia-Chen Liu; John D Fryer; Yan W Asmann; Pamela J McLean; Dennis W Dickson; Owen A Ross; Guojun Bu
Journal:  Sci Transl Med       Date:  2020-02-05       Impact factor: 19.319

6.  Commentary: α-Synuclein Interacts with Lipoproteins in Plasma.

Authors:  Andrei Surguchov
Journal:  Front Mol Neurosci       Date:  2017-11-02       Impact factor: 5.639

Review 7.  Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.

Authors:  Fatemeh Nouri Emamzadeh
Journal:  J Mol Neurosci       Date:  2017-07-10       Impact factor: 3.444

Review 8.  The Effects of Statins on Neurotransmission and Their Neuroprotective Role in Neurological and Psychiatric Disorders.

Authors:  Michał Kosowski; Joanna Smolarczyk-Kosowska; Marcin Hachuła; Mateusz Maligłówka; Marcin Basiak; Grzegorz Machnik; Robert Pudlo; Bogusław Okopień
Journal:  Molecules       Date:  2021-05-11       Impact factor: 4.411

9.  α-Synuclein Interacts with Lipoproteins in Plasma.

Authors:  Fatemeh Nouri Emamzadeh; David Allsop
Journal:  J Mol Neurosci       Date:  2017-09-08       Impact factor: 3.444

10.  Apolipoprotein E Fragmentation within Lewy Bodies of the Human Parkinson's Disease Brain.

Authors:  Troy T Rohn; Jacob M Mack
Journal:  Int J Neurodegener Dis       Date:  2018-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.